TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23597063

Group type: EXPERIMENTAL
Intervention: Assessment of oral disease (dental, periodontal, mucosal, and salivary) by dental surgeons trained in periodontology at baseline.
Number of subjects: 4500

Group type: EXPERIMENTAL
Intervention: Self-administered questionnaires evaluating oral hygiene habits and thirst.
Number of subjects: 4500

Group type: EXPERIMENTAL
Intervention: Data collection on hospitalizations and mortality (total and cause-specific) according to baseline oral health status.
Number of subjects: 4500

Group type: EXPERIMENTAL
Intervention: Evaluation of the association between periodontitis and risk of premature death in dialysis patients.
Number of subjects: 4500
Study: 21670447

Group type: EXPERIMENTAL
Intervention: Palifermin 120 μg/kg
Number of subjects: 186

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study: 19156086

Group type: EXPERIMENTAL
Intervention: Lidocaine-coated plates (versatis) applied for 12 hours during 5 days starting from the 6th day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lidocaine-coated plates (versatis)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Diclofenac 100 mg per day
Number of subjects: 60
Study: 16757825

Group type: EXPERIMENTAL
Intervention: 5 microg/kg of rFVIIa
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 20 microg/kg of rFVIIa
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 40 microg/kg of rFVIIa
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 80 microg/kg of rFVIIa
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 15575454

Group type: EXPERIMENTAL
Intervention: Social work intervention
Number of subjects: 104

Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 104
Study: 11138916

Group type: EXPERIMENTAL
Intervention: One gram azithromycin monthly
Number of subjects: 318

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 318
Study: 9301553

Group type: EXPERIMENTAL
Intervention: Indirect immunofluorescence on unfixed neutrophils
Number of subjects: 57

Group type: COMPARATOR
Intervention: Indirect immunofluorescence on ethanol fixed neutrophils
Number of subjects: 57

Group type: COMPARATOR
Intervention: Indirect immunofluorescence on acetone fixed neutrophils
Number of subjects: 57

Group type: COMPARATOR
Intervention: Indirect immunofluorescence on paraformaldehyde fixed neutrophils
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Indirect immunofluorescence on unfixed neutrophils or fixed cells
Number of subjects: 57
Study: 8359188

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 3087620

Group type: EXPERIMENTAL
Intervention: 250‐mg phenoxymethyl penicillin taken orally twice daily for one to three years
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo tablets taken orally twice daily for one to three years
Number of subjects: 32
Study: 30206744

Group type: EXPERIMENTAL
Intervention: Multimodal intervention program including usual care, multidimensional screening, verbal counselling, written instructions, home-based high-intensity functional exercise program (HIFE), and support related to cognition, mood, risk of falling, medication, nutrition and self-care.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Usual care and multimodal intervention program
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 50
Study: 28403961

Group type: EXPERIMENTAL
Intervention: Cabergoline (0.5 mg per day orally for 7 days starting from hCG administration)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Control group (no medication treatment)
Number of subjects: 146
Study: 25920921

Group type: EXPERIMENTAL
Intervention: High serum phosphorus (>5.2 mg/dL)
Number of subjects: 6797

Group type: EXPERIMENTAL
Intervention: Low serum phosphorus (<3.6 mg/dL)
Number of subjects: 6797

Group type: EXPERIMENTAL
Intervention: High serum calcium (>9.5 mg/dL)
Number of subjects: 6797

Group type: EXPERIMENTAL
Intervention: Low serum calcium (<7.9 mg/dL)
Number of subjects: 6797

Group type: EXPERIMENTAL
Intervention: High serum PTH (<168 pg/mL)
Number of subjects: 6797

Group type: EXPERIMENTAL
Intervention: Serum phosphorus at 4.4 mg/dL, calcium at 8.8 mg/dL, PTH at 398 pg/mL
Number of subjects: 6797

Group type: EXPERIMENTAL
Intervention: Decreases in serum phosphorus and calcium and increases in serum PTH
Number of subjects: 6797
Study: 23142957

Group type: EXPERIMENTAL
Intervention: MDMA repeated doses (50 mg followed by 100 mg, administered at 2 h apart)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: MDMA single dose (100 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 21190190

Group type: EXPERIMENTAL
Intervention: HPV-16/18 AS04-adjuvanted vaccine
Number of subjects: 0
Study: 19133701

Group type: EXPERIMENTAL
Intervention: 12-month course of telephone-based collaborative care
Number of subjects: 191

Group type: COMPARATOR
Intervention: Usual care by primary-care physician
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: High pain interference
Number of subjects: 191
Study: 16751008

Group type: EXPERIMENTAL
Intervention: Skin prick test with cabbage
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Double-blind placebo-controlled food challenge with cabbage
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Skin prick test with Bra o 3 (cabbage lipid transfer protein)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: CAP inhibition assays with Bra o 3
Number of subjects: 17
Study: 15384954

Group type: EXPERIMENTAL
Intervention: Combination therapy with repaglinide plus metformin
Number of subjects: 86

Group type: COMPARATOR
Intervention: Monotherapy with repaglinide
Number of subjects: 86
Study: 11374317

Group type: EXPERIMENTAL
Intervention: Tolterodine 2 mg twice daily
Number of subjects: 854
Study: 9876226

Group type: EXPERIMENTAL
Intervention: Topical corticosteroid spray (fluticasone propionate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched placebo nasal spray
Number of subjects: 0
Study: 8024097

Group type: EXPERIMENTAL
Intervention: Postoperative immunochemotherapy including OK-432
Number of subjects: 36

Group type: COMPARATOR
Intervention: Mitomycin C (MMC) and UFT
Number of subjects: 36
Study: 2504796

Group type: EXPERIMENTAL
Intervention: High fat, low carbohydrate enteral feed
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard isocaloric, isonitrogenous enteral feed
Number of subjects: 20
Study: 820365

Group type: EXPERIMENTAL
Intervention: Liquid nitrogen treatment for hand warts
Number of subjects: 1802

Group type: COMPARATOR
Intervention: Salicylic and lactic acids (SAL) paint for hand warts
Number of subjects: 1802

Group type: EXPERIMENTAL
Intervention: Concurrent treatment with liquid nitrogen and SAL paint for hand warts
Number of subjects: 1802

Group type: EXPERIMENTAL
Intervention: SAL paint for simple plantar warts
Number of subjects: 1802

Group type: COMPARATOR
Intervention: Podophyllin treatment for simple plantar warts
Number of subjects: 1802

Group type: EXPERIMENTAL
Intervention: SAL paint for mosaic plantar warts
Number of subjects: 1802

Group type: COMPARATOR
Intervention: 10% buffered gluteraldehyde for mosaic plantar warts
Number of subjects: 1802

Group type: COMPARATOR
Intervention: 40% benzalkonium chloride dibromide (Callusolve 40) for mosaic plantar warts
Number of subjects: 1802

Group type: COMPARATOR
Intervention: 5% 5-fluorouracil in dimethylsulfoxide for mosaic plantar warts
Number of subjects: 1802

Group type: COMPARATOR
Intervention: 5% idoxuridine in dimethylsulfoxide for mosaic plantar warts
Number of subjects: 1802

Group type: EXPERIMENTAL
Intervention: General practice treatment with SAL paint for hand warts and simple plantar warts
Number of subjects: 1802
Study: 30010086

Group type: EXPERIMENTAL
Intervention: Standard care + NRT sampling
Number of subjects: 22

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 22
Study: 28169410

Group type: EXPERIMENTAL
Intervention: Policosanol + aspirin
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo + aspirin
Number of subjects: 80
Study: 25633468

Group type: EXPERIMENTAL
Intervention: 500 mg mesalazine
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Rapid desensitization protocol
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 24154647

Group type: EXPERIMENTAL
Intervention: Nutritional supplement drinks provided three times on intervention day, each drink providing 283.3+/‐41.8 Kcal and 13.8+/‐4.7g of protein
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control day (no nutritional supplement drinks)
Number of subjects: 26
Study: 21139252

Group type: EXPERIMENTAL
Intervention: Intracoronary irradiation with liquid Rhenium-188-filled balloon after cutting balloon angioplasty (CBA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no brachytherapy)
Number of subjects: 50
Study: 18326606

Group type: EXPERIMENTAL
Intervention: High-protein diet (HP: 2 g x kg(‐1) x d(‐1))
Number of subjects: 8

Group type: COMPARATOR
Intervention: Normal-protein diet (NP: 1 g x kg(‐1) x d(‐1))
Number of subjects: 8
Study: 16543072

Group type: EXPERIMENTAL
Intervention: Pegfilgrastim 6 mg on day 1 posttransplant
Number of subjects: 20

Group type: COMPARATOR
Intervention: Filgrastim 5 microg/kg daily starting on day 1 posttransplant
Number of subjects: 20
Study: 15008243

Group type: EXPERIMENTAL
Intervention: 3 daily administrations of cortisone acetate (3/6 of the daily dose early in the morning, 2/6 after lunch, 1/6 after dinner)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 3 daily administrations of cortisone acetate
Number of subjects: 34

Group type: COMPARATOR
Intervention: 2 daily administrations of cortisone acetate (2/3 of the total daily dose early in the morning, 1/3 in the afternoon)
Number of subjects: 34
Study: 11119193

Group type: EXPERIMENTAL
Intervention: Combined epidural and general anaesthesia (EPI group)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Deep opioid anaesthesia (DOA group)
Number of subjects: 24
Study: 9198564

Group type: EXPERIMENTAL
Intervention: Laparoscopic resection
Number of subjects: 111

Group type: COMPARATOR
Intervention: Conventional approach
Number of subjects: 111
Study: 8198813

Group type: EXPERIMENTAL
Intervention: Nerisona ointment (DFV)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Nerisalic ointment (DFV + salicylic acid)
Number of subjects: 2
Study: 4028620

Group type: EXPERIMENTAL
Intervention: Intravenous acebutolol (25 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intravenous acebutolol (50 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Oral acebutolol (200 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Oral acebutolol (400 mg)
Number of subjects: 24
Study: 30516501

Group type: EXPERIMENTAL
Intervention: Biofeedback therapy and Cytoflavin in addition to standard treatment
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard treatment (non-steroidal anti-inflammatory drugs, myorelaxants, chondroprotectors, physiotherapy)
Number of subjects: 150
Study: 26086613

Group type: EXPERIMENTAL
Intervention: AUC truncated at 48 hr
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: AUC truncated at 24 hr
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: AUC truncated at 12 hr
Number of subjects: 28

Group type: COMPARATOR
Intervention: AUC truncated at 72 hr
Number of subjects: 28
Study: 24844921

Group type: EXPERIMENTAL
Intervention: Active phototherapy with 905 nm super‐pulsed laser and 875 and 640 nm LEDs, 12 treatments
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo phototherapy device, 12 treatments
Number of subjects: 86
Study: 24821009

Group type: EXPERIMENTAL
Intervention: Biweekly regimen of gemcitabine (1,000 mg/m² on days 1 and 14) and carboplatin (AUC = 3 on days 1 and 14) every 28 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard regimen of gemcitabine (1,000 mg/m² on days 1 and 8) and carboplatin (AUC = 5 on day 1) every 21 days
Number of subjects: 40
Study: 21058850

Group type: EXPERIMENTAL
Intervention: Stress Management Training (SMT) based on acceptance and commitment therapy, n = 177
Number of subjects: 311

Group type: COMPARATOR
Intervention: Waitlist control group, n = 134
Number of subjects: 311
Study: 19079276

Group type: EXPERIMENTAL
Intervention: Watching TV
Number of subjects: 538

Group type: EXPERIMENTAL
Intervention: Playing video and computer games
Number of subjects: 538

Group type: EXPERIMENTAL
Intervention: Physical activity (moderate, 3.5 METs)
Number of subjects: 538

Group type: EXPERIMENTAL
Intervention: Reading/doing homework
Number of subjects: 538
Study: 16887369

Group type: EXPERIMENTAL
Intervention: Endovascular Aneurysm Repair (EVAR)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Open Aneurysm Repair (OAR)
Number of subjects: 32
Study: 12594104

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MD)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control diet (CD)
Number of subjects: 51
Study: 11000669

Group type: EXPERIMENTAL
Intervention: 2% sevoflurane
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 4% sevoflurane
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 6% sevoflurane
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 8% sevoflurane
Number of subjects: 120
Study: 8633511

Group type: EXPERIMENTAL
Intervention: L-365,260 administered every 6 hours over a 5-7 day period
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: L-365,260
Number of subjects: 0
Study: 1604908

Group type: EXPERIMENTAL
Intervention: Sodium fluoride (NaF) tablets for 7 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sodium monofluorophosphate (MFP) tablets for 7 days
Number of subjects: 20
Study: 3533891

Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 290

Group type: COMPARATOR
Intervention: Cefamandole
Number of subjects: 290
Study: 29379282

Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation (PR) - 12-week program, 3 sessions per week, 60 minutes per session
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group - waiting list for admission to PR program
Number of subjects: 74
Study: 26548425

Group type: EXPERIMENTAL
Intervention: Anthocyanins (AC)‐rich extract from red oranges, 200 mg administered in two doses (12 and 4 hours before diving)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no anthocyanins supplementation)
Number of subjects: 16
Study: 23857943

Group type: EXPERIMENTAL
Intervention: Williams LifeSkills training (WLST) for 8 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 60
Study: 22402919

Group type: EXPERIMENTAL
Intervention: Partial stapled hemorrhoidopexy (PSH)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Circular stapled hemorrhoidopexy (CSH)
Number of subjects: 72
Study: 20189810

Group type: EXPERIMENTAL
Intervention: VR group (n=9)
Number of subjects: 12

Group type: COMPARATOR
Intervention: NVR group (n=9)
Number of subjects: 12
Study: 18678163

Group type: EXPERIMENTAL
Intervention: Simple acupuncture
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Slowly twirling needle
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Rapidly twirling needle
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Simple lifting-thrusting
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Lifting-thrusting-twirling needle
Number of subjects: 172
Study: 15929034

Group type: EXPERIMENTAL
Intervention: High-dose methotrexate alone
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: High-dose methotrexate with deferred radiotherapy
Number of subjects: 37

Group type: COMPARATOR
Intervention: High-dose methotrexate without whole-brain radiotherapy
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: High-dose methotrexate
Number of subjects: 37
Study: 12828493

Group type: EXPERIMENTAL
Intervention: Fluorouracil plus levamisole and folinic acid (B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluorouracil plus levamisole (A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Markov model results (B versus A)
Number of subjects: 0
Study: 9988142

Group type: EXPERIMENTAL
Intervention: RenaGel
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: RenaGel with calcium (900 mg elemental, once-nightly on an empty stomach)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control (washout periods)
Number of subjects: 71
Study: 7786885

Group type: EXPERIMENTAL
Intervention: Apomorphine HCl (0.5 mg sc)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Blood sampling during apomorphine administration
Number of subjects: 1
Study: 2151747

Group type: COMPARATOR
Intervention: 20 mg BY 1023/SK&F 96022
Number of subjects: 12

Group type: COMPARATOR
Intervention: 40 mg BY 1023/SK&F 96022
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 713424

Group type: EXPERIMENTAL
Intervention: 3.5 microgram/kg carbachol
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 0.6 microgram/kg pentagastrin
Number of subjects: 25

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 25
Study: 30862692

Group type: EXPERIMENTAL
Intervention: Circulating tumor DNA (ctDNA) detection before NAT
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Undetectable ctDNA at baseline
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Persistent ctDNA detection at baseline and week 2
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Event-free survival (EFS) analysis
Number of subjects: 455
Study: 26776270

Group type: EXPERIMENTAL
Intervention: Local RUTF (alternative formulations using local ingredients)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Local RUTF
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard RUTF (peanut-based with powdered milk)
Number of subjects: 200
Study: 25947578

Group type: EXPERIMENTAL
Intervention: txt4two intervention (mHealth intervention promoting healthy nutrition, physical activity, and GWG)
Number of subjects: 100
Study: 22524182

Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Ankle foot orthosis (Control)
Number of subjects: 16
Study: 21222186

Group type: EXPERIMENTAL
Intervention: Heat stress (HS) applied to the belly of the vastus lateralis during resistance exercise
Number of subjects: 8
Study: 19255015

Group type: EXPERIMENTAL
Intervention: Resuscitation with room air or 100% oxygen using pulse oximetry
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Use of colorimetric carbon dioxide detectors during bag-and-mask ventilation
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Target peak inspiratory pressure of 30 cm H(2)O
Number of subjects: 24
Study: 16545706

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with 1:200,000 epinephrine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.5% levobupivacaine with 1:200,000 epinephrine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both solutions
Number of subjects: 30

Group type: COMPARATOR
Intervention: 0.5% bupivacaine with 1:200,000 epinephrine and 0.5% levobupivacaine with 1:200,000 epinephrine
Number of subjects: 30
Study: 12736013

Group type: EXPERIMENTAL
Intervention: 1 microM N/OFQ
Number of subjects: 14

Group type: COMPARATOR
Intervention: 1 microM [desPhe(1)]N/OFQ (placebo)
Number of subjects: 14
Study: 10789612

Group type: EXPERIMENTAL
Intervention: Niaspan (extended-release niacin) at doses of 1500 and 2000 mg
Number of subjects: 173

Group type: COMPARATOR
Intervention: Gemfibrozil 600 mg given twice daily
Number of subjects: 173
Study: 9757699

Group type: EXPERIMENTAL
Intervention: Clemastin
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Phenazolinum
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Zyrtec
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Astemizol
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Claritin
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Disophrol
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 8161442

Group type: EXPERIMENTAL
Intervention: HIV-1 immunogen
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 3518407

Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg, tid orally for 1 week
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31996042

Group type: EXPERIMENTAL
Intervention: Extracorporeal septal reconstruction (ESR)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Endonasal septoplasty (ES)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 46
Study: 29624694

Group type: EXPERIMENTAL
Intervention: Neuroplasticity-oriented targeted cognitive training for 4 weeks
Number of subjects: 61

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Neuroplasticity-oriented targeted cognitive training
Number of subjects: 61
Study: 26857887

Group type: EXPERIMENTAL
Intervention: Standardized resistance training performed three times a week for 15 weeks under supervision of a physiotherapist
Number of subjects: 60

Group type: COMPARATOR
Intervention: Unchanged physical activity (control group)
Number of subjects: 60
Study: 24294838

Group type: COMPARATOR
Intervention: Contingency Management (CM)
Number of subjects: 337

Group type: COMPARATOR
Intervention: Assertive Continuing Care (ACC)
Number of subjects: 337

Group type: COMPARATOR
Intervention: Combination of CM + ACC
Number of subjects: 337
Study: 22430025

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided injection (4 mL of 0.5% bupivacaine and 40 mg methylprednisone)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Fluoroscopic-guided injection (4 mL of 0.5% bupivacaine and 40 mg methylprednisone)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided injection
Number of subjects: 23

Group type: COMPARATOR
Intervention: Fluoroscopic-guided injection
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided injection and Fluoroscopic-guided injection
Number of subjects: 23
Study: 20831536

Group type: EXPERIMENTAL
Intervention: Gliclazide 80 mg
Number of subjects: 18
Study: 18050054

Group type: EXPERIMENTAL
Intervention: Exercise group (EG)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 30
Study: 16645536

Group type: EXPERIMENTAL
Intervention: Topical micellar nanoparticle estradiol emulsion (MNPEE; 3.45 g daily dose containing 8.6 mg estradiol)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo emulsion
Number of subjects: 200
Study: 12417166

Group type: EXPERIMENTAL
Intervention: Tourniquet used without exsanguination
Number of subjects: 11

Group type: COMPARATOR
Intervention: No tourniquet used (control)
Number of subjects: 11